Literature DB >> 8971014

Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus.

B M Kerr1, N Kienzle, J M Burrows, S Cross, S L Silins, M Buck, E M Benson, B Coupar, D J Moss, T B Sculley.   

Abstract

Persistent Epstein-Barr virus (EBV) infection is primarily controlled by HLA class I-restricted memory cytotoxic T-cell (CTL) responses which can be reactivated in vitro by stimulation of peripheral blood lymphocytes with autologous lymphoblastoid cell lines. During an investigation of a donor infected by both type A and type B EBV, CTL specific for type B EBV were isolated. The CTL were found to recognize an epitope encoded by the EBNA-6B gene. The minimal epitope sequence was identified as QNGALAINTF, corresponding to residues 213 to 222 in the EBNA-6B protein, and presentation of this epitope was shown to be via HLA B62 (B15). This is the first report of the characterization of an epitope that is EBV type B specific. CTL recognizing sequences common to type A and type B EBV were identified as well. A cross-reactive epitope recognized by these CTL was encoded within the EBNA-6 gene of both type A and type B. This minimal sequence for this epitope was LLDFVRFMGV (residues 284 to 293 in both types), and the epitope was restricted through HLA A*0201. This second epitope sequence overlaps with a published EBV B44-restricted epitope (EENLLDFVRF). The implications of these findings are discussed with respect to the design and efficacy of epitope-based vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8971014      PMCID: PMC190982     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.

Authors:  S R Burrows; I S Misko; T B Sculley; C Schmidt; D J Moss
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

2.  Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.

Authors:  C D Gregory; M Rowe; A B Rickinson
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

3.  Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.

Authors:  T B Sculley; A Apolloni; R Stumm; D J Moss; N Mueller-Lantczh; I S Misko; D A Cooper
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

4.  Detection of a second widespread strain of Epstein-Barr virus.

Authors:  J W Sixbey; P Shirley; P J Chesney; D M Buntin; L Resnick
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

5.  Characterization of EBV-carrying B-cell populations in healthy seropositive individuals with regard to density, release of transforming virus and spontaneous outgrowth.

Authors:  N Lewin; P Aman; M G Masucci; E Klein; G Klein; B Oberg; H Strander; W Henle; G Henle
Journal:  Int J Cancer       Date:  1987-04-15       Impact factor: 7.396

6.  Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.

Authors:  D J Moss; I S Misko; S R Burrows; K Burman; R McCarthy; T B Sculley
Journal:  Nature       Date:  1988-02-25       Impact factor: 49.962

7.  Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.

Authors:  R J Murray; M G Kurilla; H M Griffin; J M Brooks; M Mackett; J R Arrand; M Rowe; S R Burrows; D J Moss; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

8.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

9.  Epstein-Barr virus genotypes associated with nasopharyngeal carcinoma in southern China.

Authors:  M L Lung; R S Chang; M L Huang; H Y Guo; D Choy; J Sham; S Y Tsao; P Cheng; M H Ng
Journal:  Virology       Date:  1990-07       Impact factor: 3.616

10.  The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants.

Authors:  M E Andrew; B E Coupar; D B Boyle; G L Ada
Journal:  Scand J Immunol       Date:  1987-01       Impact factor: 3.487

View more
  8 in total

1.  Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood.

Authors:  W Herr; E Ranieri; A Gambotto; L S Kierstead; A A Amoscato; L Gesualdo; W J Storkus
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers.

Authors:  Brigitte Gückel; Christine Rentzsch; Maria-Dorothea Nastke; Alexander Marmé; Ines Gruber; Stefan Stevanović; Simone Kayser; Diethelm Wallwiener
Journal:  J Cancer Res Clin Oncol       Date:  2005-12-22       Impact factor: 4.553

3.  Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.

Authors:  S Pepperl; G Benninger-Döring; S Modrow; H Wolf; W Jilg
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

4.  Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination.

Authors:  E Ranieri; W Herr; A Gambotto; W Olson; D Rowe; P D Robbins; L S Kierstead; S C Watkins; L Gesualdo; W J Storkus
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Cross-reactivity of T lymphocytes recognizing a human cytotoxic T-lymphocyte epitope within BK and JC virus VP1 polypeptides.

Authors:  Ludmila Krymskaya; Madeva C Sharma; Joy Martinez; Wahajul Haq; Eric C Huang; Ajit P Limaye; Don J Diamond; Simon F Lacey
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

6.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

7.  Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis.

Authors:  P Höllsberg; H J Hansen; S Haahr
Journal:  Clin Exp Immunol       Date:  2003-04       Impact factor: 4.330

8.  Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Authors:  Florian K Bihl; Elisabetta Loggi; John V Chisholm; Hannah S Hewitt; Leah M Henry; Caitlyn Linde; Todd J Suscovich; Johnson T Wong; Nicole Frahm; Pietro Andreone; Christian Brander
Journal:  J Transl Med       Date:  2005-05-11       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.